Journal article
Assumptions of Expected Benefits in Randomized Phase III Trials Evaluating Systemic Treatments for Cancer
Abstract
BACKGROUND: In designing phase III randomized clinical trials (RCTs), the expected magnitude of the benefit of the experimental therapy (δ) determines the number of patients required and the number of person-years of follow-up. We conducted a systematic review to evaluate how reliably δ approximates the observed benefit (B) in RCTs that evaluated cancer treatment.
METHODS: RCTs evaluating systemic therapy in adult cancer patients published in …
Authors
Gan HK; You B; Pond GR; Chen EX
Journal
Journal of the National Cancer Institute, Vol. 104, No. 8, pp. 590–598
Publisher
Oxford University Press (OUP)
Publication Date
April 18, 2012
DOI
10.1093/jnci/djs141
ISSN
0027-8874